These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34960665)

  • 21. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
    Torriani FJ; Komarow L; Parker RA; Cotter BR; Currier JS; Dubé MP; Fichtenbaum CJ; Gerschenson M; Mitchell CK; Murphy RL; Squires K; Stein JH;
    J Am Coll Cardiol; 2008 Aug; 52(7):569-76. PubMed ID: 18687253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Geretti AM; Fox Z; Johnson JA; Booth C; Lipscomb J; Stuyver LJ; Tachedjian G; Baxter J; Touloumi G; Lehmann C; Owen A; Phillips A;
    PLoS One; 2013; 8(7):e69266. PubMed ID: 23874928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System.
    Moure R; Domingo P; Villarroya J; Gasa L; Gallego-Escuredo JM; Quesada-López T; Morón-Ros S; Maroto AF; Mateo GM; Domingo JC; Villarroya F; Giralt M
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29661866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.
    Bélanger AS; Caron P; Harvey M; Zimmerman PA; Mehlotra RK; Guillemette C
    Drug Metab Dispos; 2009 Sep; 37(9):1793-6. PubMed ID: 19487252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efavirenz severe hypersensitivity reaction: case report and rapid desensitization protocol development.
    Khalili H; Farasatinasab M; Hajiabdolbaghi M
    Ann Pharmacother; 2012 May; 46(5):e12. PubMed ID: 22535841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
    Squires K; Lazzarin A; Gatell JM; Powderly WG; Pokrovskiy V; Delfraissy JF; Jemsek J; Rivero A; Rozenbaum W; Schrader S; Sension M; Vibhagool A; Thiry A; Giordano M
    J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1011-9. PubMed ID: 15247553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
    DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR;
    Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
    Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
    J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
    Bacheler LT; Anton ED; Kudish P; Baker D; Bunville J; Krakowski K; Bolling L; Aujay M; Wang XV; Ellis D; Becker MF; Lasut AL; George HJ; Spalding DR; Hollis G; Abremski K
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2475-84. PubMed ID: 10952598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy.
    Karamchand S; Leisegang R; Schomaker M; Maartens G; Walters L; Hislop M; Dave JA; Levitt NS; Cohen K
    Medicine (Baltimore); 2016 Mar; 95(9):e2844. PubMed ID: 26945366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer-Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and
    Surve DH; Jirwankar YB; Dighe VD; Jindal AB
    Mol Pharm; 2020 Oct; 17(10):3990-4003. PubMed ID: 32808785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
    Dubé MP; Komarow L; Mulligan K; Grinspoon SK; Parker RA; Robbins GK; Roubenoff R; Tebas P;
    J Acquir Immune Defic Syndr; 2007 Aug; 45(5):508-14. PubMed ID: 17589373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
    Kuritzkes DR; Ribaudo HJ; Squires KE; Koletar SL; Santana J; Riddler SA; Reichman R; Shikuma C; Meyer WA; Klingman KL; Gulick RM;
    J Infect Dis; 2007 Apr; 195(8):1169-76. PubMed ID: 17357053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.
    Redhage LA; Shintani A; Haas DW; Emeagwali N; Markovic M; Oboho I; Mwenya C; Erdem H; Acosta EP; Morrow JD; Hulgan T
    HIV Clin Trials; 2009; 10(3):181-92. PubMed ID: 19632957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
    Jemsek JG; Arathoon E; Arlotti M; Perez C; Sosa N; Pokrovskiy V; Thiry A; Soccodato M; Noor MA; Giordano M
    Clin Infect Dis; 2006 Jan; 42(2):273-80. PubMed ID: 16355341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.
    Tashima K; Staszewski S; Nelson M; Rachlis A; Skiest D; Stryker R; Bessen L; Overfield S; Ruiz N; Wirtz V
    AIDS; 2008 Jan; 22(2):275-9. PubMed ID: 18097230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
    Haubrich RH; Riddler SA; DiRienzo AG; Komarow L; Powderly WG; Klingman K; Garren KW; Butcher DL; Rooney JF; Haas DW; Mellors JW; Havlir DV;
    AIDS; 2009 Jun; 23(9):1109-18. PubMed ID: 19417580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
    Hukezalie KR; Thumati NR; Côté HC; Wong JM
    PLoS One; 2012; 7(11):e47505. PubMed ID: 23166583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.
    Mitchell D; Israr M; Alam S; Dinello D; Kishel J; Jia R; Meyers C
    HIV Med; 2014 Apr; 15(4):196-202. PubMed ID: 24580719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.